These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33917026)

  • 41. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck.
    Carter RJ; Milani M; Butterworth M; Alotibi A; Harper N; Yedida G; Greaves G; Al-Zebeeby A; Jorgensen AL; Schache AG; Risk JM; Shaw RJ; Jones TM; Sacco JJ; Hurlstone A; Cohen GM; Varadarajan S
    Cell Death Dis; 2019 Dec; 10(12):912. PubMed ID: 31801952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations.
    Henz K; Al-Zebeeby A; Basoglu M; Fulda S; Cohen GM; Varadarajan S; Vogler M
    Biol Chem; 2019 Jan; 400(2):181-185. PubMed ID: 29924730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
    Yu L; Liu S
    Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. It's time to die: BH3 mimetics in solid tumors.
    Kehr S; Vogler M
    Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118987. PubMed ID: 33600840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional apoptosis profiling identifies MCL-1 and BCL-xL as prognostic markers and therapeutic targets in advanced thymomas and thymic carcinomas.
    Müller D; Mazzeo P; Koch R; Bösherz MS; Welter S; von Hammerstein-Equord A; Hinterthaner M; Cordes L; Belharazem D; Marx A; Ströbel P; Küffer S
    BMC Med; 2021 Nov; 19(1):300. PubMed ID: 34781947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
    Stauffer SR
    Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bh3 induced conformational changes in Bcl-Xl revealed by crystal structure and comparative analysis.
    Rajan S; Choi M; Baek K; Yoon HS
    Proteins; 2015 Jul; 83(7):1262-72. PubMed ID: 25907960
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer.
    Khawaja H; Briggs R; Latimer CH; Rassel M; Griffin D; Hanson L; Bardelli A; Di Nicolantonio F; McDade SS; Scott CJ; Lambe S; Maurya M; Lindner AU; Prehn JHM; Sousa J; Winnington C; LaBonte MJ; Ross S; Van Schaeybroeck S
    Mol Cancer Ther; 2023 Jan; 22(1):135-149. PubMed ID: 36279564
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of BH3-mimetics on Human and Mouse Blood Leukocytes: A Comparative Study.
    Rohner L; Reinhart R; Iype J; Bachmann S; Kaufmann T; Fux M
    Sci Rep; 2020 Jan; 10(1):222. PubMed ID: 31937836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.
    Koss B; Ryan J; Budhraja A; Szarama K; Yang X; Bathina M; Cardone MH; Nikolovska-Coleska Z; Letai A; Opferman JT
    Oncotarget; 2016 Mar; 7(10):11500-11. PubMed ID: 26862853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics.
    Koessinger AL; Cloix C; Koessinger D; Heiland DH; Bock FJ; Strathdee K; Kinch K; Martínez-Escardó L; Paul NR; Nixon C; Malviya G; Jackson MR; Campbell KJ; Stevenson K; Davis S; Elmasry Y; Ahmed A; O'Prey J; Ichim G; Schnell O; Stewart W; Blyth K; Ryan KM; Chalmers AJ; Norman JC; Tait SWG
    Cell Death Differ; 2022 Oct; 29(10):2089-2104. PubMed ID: 35473984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anticancer effects of putative and validated BH3-mimetic drugs in head and neck squamous cell carcinomas: An overview of current knowledge.
    Melo G; Silva CAB; Hague A; Parkinson EK; Rivero ERC
    Oral Oncol; 2022 Sep; 132():105979. PubMed ID: 35816876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
    Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
    Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma.
    Karpel-Massler G; Ishida CT; Zhang Y; Halatsch ME; Westhoff MA; Siegelin MD
    Expert Opin Drug Discov; 2017 Oct; 12(10):1031-1040. PubMed ID: 28712306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.
    Peperzak V; Slinger E; Ter Burg J; Eldering E
    Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BCL-XL inhibition induces an FGFR4-mediated rescue response in colorectal cancer.
    Ramesh P; Di Franco S; Atencia Taboada L; Zhang L; Nicotra A; Stassi G; Medema JP
    Cell Rep; 2022 Feb; 38(7):110374. PubMed ID: 35172148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.